Increased endogenous glucose production (EGP) and gluconeogenesis contribute to the pathogenesis of hyperglycaemia in non-insulin-dependent diabetes mellitus (NIDDM). In healthy subjects, however, EGP remains constant during administration of gluconeogenic precursors. This study was performed in order to determine whether administration of fructose increases EGP in obese NIDDM patients and obese non-diabetic subjects. Eight young healthy lean subjects, eight middle-aged obese NIDDM patients and seven middle-aged obese non-diabetic subjects were studied during hourly ingestion of 13C fructose (0.3 g. kg fat free mass -1 9 h -1) for 3 h. Fructose failed to increase EGP (measured with 6,6 2H glucose) in NIDDM (17.7 + 1.9 #mol. kg fat free mass -1. min -~ basal vs 15.9 _+ 0.9 after fructose), in obese non-diabetic subjects (12.1+0.5 basal vs 13.1 + 0.5 after fructose) and in lean healthy subjects (13.3 + 0.5 basal vs 13.8 + 0.6 after fructose) although ~3C glucose synthesis contributed 73.2 % of EGP in lean subjects, 62.6 % in obese non-diabetic subjects, and 52.8 % in obese NIDDM patients. Since glucagon may play an important role in the development of hyperglycaemia in NIDDM, healthy subjects were also studied during 13C fructose ingestion + hyperglucagonaemia (232 + 9 ng/1) and during hyperglucagonaemia alone. EGP increased by 19.8 % with ingestion of fructose + glucagon (p < 0.05) but remained unchanged during administration of fructose or glucagon alone. The plasma ~3C glucose enrichment was identical after fructose ingestion both with and without glucagon, indicating that the contribution of fructose gluconeogenesis to the glucose 6-phosphate pool was identical in these two conditions. We concluded that during fructose administration: 1) gluconeogenesis is increased, but EGP remains constant in NIDDM, obese non-diabetic, and lean individuals; 2) in lean individuals, both an increased glucagonaemia and an enhanced supply of gluconeogenic precursors are required to increase EGP; this increase in EGP occurs without changes in the relative proportion of glucose 6-phosphate production from fructose and from other sources (i. e. glycogenolysis + gluconeogenesis from non-fructose precursors). [Diabetologia (1996) 39: 580-586] Keywords Glycogenolysis, carbohydrate oxidation, glucagon, gluconeogenesis, fructose.
studied during 13C fructose ingestion + hyperglucagonaemia (232 + 9 ng/1) and during hyperglucagonaemia alone. EGP increased by 19.8 % with ingestion of fructose + glucagon (p < 0.05) but remained unchanged during administration of fructose or glucagon alone. The plasma ~3C glucose enrichment was identical after fructose ingestion both with and without glucagon, indicating that the contribution of fructose gluconeogenesis to the glucose 6-phosphate pool was identical in these two conditions. We concluded that during fructose administration: 1) gluconeogenesis is increased, but EGP remains constant in NIDDM, obese non-diabetic, and lean individuals; 2) in lean individuals, both an increased glucagonaemia and an enhanced supply of gluconeogenic precursors are required to increase EGP; this increase in EGP occurs without changes in the relative proportion of glucose 6-phosphate production from fructose and from other sources (i. e. glycogenolysis + gluconeogenesis from non-fructose precursors). [Diabetologia (1996) 39: 580-586] to rise when gluconeogenic substrates are infused and gluconeogenesis is increased [1] [2] [3] [4] [5] . This constancy of EGP was also observed during infusions of lactate [2] or fructose [5] when insulin and glucagon were maintained constant by infusions of somatostatin, insulin and glucagon, indicating autoregulation. The mechanisms responsible for this autoregulation of EGP may involve inhibition of gluconeogenesis from endogenous substrates [3] and/or of glucogenolysis [2] and stimulation of glycogen synthesis [5] . In non-insulin-dependent diabetic (NIDDM) patients, EGP is increased and correlates with fasting plasma glucose [6] . Hepatic balance of gluconeogenic precursors [7] , estimation of hepatic glycogen degradation by in vivo nuclear magnetic resonance spectroscopy [8] and assessment of Cori cycle activity [9] , all indicate that an increased gluconeogenesis accounts for a substantial part of this increase in EGR It may be hypothesized that a rise in gluconeogenic substrate availability [10, 11] secondary to peripheral insulin resistance is responsible for both stimulation of gluconeogenesis and EGR In the first part of this study, we measured the alterations induced by fructose ingestion on whole body and hepatic glucose metabolism in young lean healthy control subjects, in middle-aged obese non-diabetic subjects, and in middleaged obese NIDDM patients.
The second part ,of this study aimed to assess whether the alterations of the regulation of glucagon secretion which are frequently encountered in NIDDM might alter the regulation of EGP during fructose administration. It has been shown that glucagon secretion is increased, or inappropriately decreased in NIDDM patients following meals. Moreover, this relative hyperglucagonaemia has been shown to participate in the development of hyperglycaemia [12] . We have also shown that amino acids increase EGP when infused together with exogenous glucose [13] or during hyperinsulinaemic clamps and that amino acid-induced glucagon secretion plays a pivotal role in stimulating EGI? in this condition [14] . We therefore assessed the effect of hyperglucagonaemia on fructose-induced gluconeogenesis and on EPG in lean healthy subjects.
Subjects and methods
Subjects. Eight young healthy human volunteers [four males, four females, age 23.1+0.8years (mean +_ SEM), weight 71.7 _+ 3.7 kg, height 174.1 _+ 1.9 cm, fat free mass (FFM) (determined from skinfold thickness measurements [15] ) 56.0_+ 3.7 kg] were selected to participate in three protocols. All were in good physical health, were not currently taking any medication, and had no family history of diabetes or related disorders. Eight middle-aged obese NIDDM patients (four males, four females, mean age 55.5 _+ 3.0 years, weight 88.2 _+ 6.8 kg, height 167.4 _+ 2.4 cm, FFM 52.6 _+ 2.5 kg) and 7 middle-aged obese subjects with normal glucose tolerance (assessed with a standard 75-g oral glucose tolerance test) (seven females, mean age 41.1 _+ 4.1 years, weight 92.8 + 4.6 kg, height 164.5 _+ 2.5 cm, FFM 54.5 + 3.9 kg were recruited to participate in protocol 1. NIDDM subjects were maintained in good metabolic control with oral anti-diabetic agents (mean HbAlo 5.9 _+ 0.9 %) and were not taking any other medication. They discontinued all drug treatment 4 days prior to the study. All subjects had maintained a steady body weight for at least 3 months before taking part in the study. They were placed on an isocaloric, 50 % carbohydrate diet devoid of foods naturally enriched in 13C during the 3 days preceding each study.
Experimental protocols were approved by the ethical committees of Lausanne and Liege Schools of Medicine.
General procedures.
All experiments began between 07.00 and 09.00 hours after: a 10-12-h fast. After having voided urine, the subjects lay in the supine position and an indwelling venous cannula was inserted into an antecubital vein of one arm. A primed (3000 ~tg/kg) continuous (30 ~tg. kg 1. min-1) infusion of 6,6 2H glucose (1 g/l; Isotech Inc., Miamisburg, Ohio, USA) was started at time -180 min and was continued throughout the 6-h experiment. A second cannula was inserted into a wrist vein of the contralateral arm and was used to collect blood samples periodically between time -30 and 180 rain. This hand was placed in a thermostabilized box heated to 60 ~ in order to achieve partial arterialization of venous blood (oxygen saturation 70-80%). Respiratory gas exchanges were monitored between -60 and 180 min by continuous flow indirect calorimetry, using a ventilated canopy [16] . The air at the inlet and outlet of the canopy was continuously analysed for 02 (Magnos 3G delta; Hartmann and Braun, Frankfurt, Germany) and CO 2 (Uras 3G delta; Hartmann and Braun), and the total air flow through the canopy was measured with a digital pneumotachograph (Godart-stathan BV, Bilthoven, The Netherlands). Breath samples were collected at intervals for determination of ~3CO2.
Protocol h Eight young healthy subjects, seven middle-aged obese non-diabetic subjects, and eight middle-aged obese NIDDM patients took part in this protocol. After a 2-h equilibration period, baseline data were collected between -60 and 0 rain. Subsequently a fructose load (300 mg/kg FFM, dissolved in 50 ml lemon-flavoured water) enriched with 1-13C fructose (Isotech Inc.) at 1.113 % 13C was administered orally once every hour until time 180 rain. It was assumed that the total amount of fructose absorbed during the period 120-180 rain was 300 mg/kg FFM, or 5 mg -kg FFM -~ .min-<
The eight healthy subjects studied in protocol 1 also participated in protocols 2 and 3.
Protocol 2:
This protocol was identical to protocol i but, in addition, glucagon (Glucag~ne; Novo Nordisk, Copenhagen, Denmark) was infused at a rate of 3 ng. kg -I 9 rain -1 between 0 and 180 min.
Protocol 3:
This protocol was designed to evaluate the effects of hyperglucagonaemia alone on glucose production and oxidation. For this purpose, subjects were infused with glucagon at a rate of 3 ng -kg 1. min-1 between 0 and 180 min, but did not receive any fructose.
Glucose kinetics: Glucose rates of appearance (which were equal to EGP) and of disappearance (GR~) were calculated from plasma 6,6 2H enrichment during the periods -30-0 min and 120-180 rain. Steele's equations for steady-state conditions were used for this purpose [17] . The contribution of gluconeogenesis from fructose to EGP (EGP(F)) was calculated during the period 300-360 min from the rate of 13C glucose appearance using the equation of Chiasson et al. [18] . Glucose production from sources other than fructose (EGP(~on.F)) (i. e. from glycogenolysis and gluconeogenesis from lactate, amino acids and glycerol) was calculated as:
Substrate oxidation rates. Net carbohydrate oxidation rates were calculated from respiratory gas exchanges and urinary nitrogen excretion corrected for changes in blood urea nitrogen [19] using the equations of Livesey and Ella [20] . 13C fructose oxidation was calculated as: ap < 0.05 VS basal; bp < 0.01 vs basal; Cp < 0.001 vs basal; dp < 0.05 VS lean control subjects; ep < 0.01 VS lean control subjects 13CO 2 and infused 13C fructose are expressed in atom % excess (APE) and VCO2 in ml/min; FFM is fat-free mass in kg and 0.8 is a correction for incomplete recovery of 13CO2 in breath [21] ; 0.134 is the ml of CO2 produced during oxidation of i [xmol fructose. Non-oxidative fructose disposal was calculated as: Non-ox FD = fructose ingested -13C fructose ox Non-ox FD represents mainly glucose synthesis from fructose with glycogen deposition of the neoformed glucose and de novo lipogenesis from fructose. However, the latter process appears to be quantitatively small.
Analytical procedures. Plasma 6, 6 2H glucose was measured by GC-MS (HP) of penta-acetylated glucose in electron impact mode, with selected monitoring of m/z 242.1 and 244.1. Plasma 13C glucose was purified by HPLC [22] and analysed by isotope ratio mass spectrometry (Roboprep CN/Tracermass; Europa Scientific, Crewe, U.K.). Breath 13CO2 was measured by isotope ratio mass spectrometry (Roboprep g/Tracermass; Europa Scientific). Plasma insulin (kit from Biodata SpA, Guidonia Montecelio, Italy) and glucagon (kit KGND1; DPC, Los Angeles, Calif., USA) were measured by radioimmunoassay. Plasma and urine fructose [23] were measured enzymatically. Plasma non-esterified fatty acids were measured colorimetrically using a kit from Wako (Freiburg, Germany). Urinary nitrogen was measured with the method of Kjehldahl [24] .
between healthy subjects during protocols 1, 2 and 3 were performed with modified analysis of variance and paired t-tests.
Results
Basal substrate and hormone concentrations are shown in Table 1 . NIDDM patients had a 55 % increase in plasma glucose concentration (p < 0.01) and 47 % increase in plasma non-esterified fatty acid concentrations (NS), and obese non-diabetic subjects had an 80 % increase in plasma non-esterified fatty acid concentrations (NS) vs lean healthy subjects. Net carbohydrate (CHO) oxidation in the basal state averaged 11.4 + 1.1 ~tmol 9 kg FFM -1 9 min -1 in healthy subjects, 7.8 + 1.5 ~tmol 9 kg FFM -1 9 rain -1 in obese non-diabetic subjects (NS) and 8.2-0.6 {tmol 9 kg FFM -1 9 min -~ in NIDDM patients (p < 0.05 vs lean healthy subjects). Basal EGP was increased by 33.1% in NIDDM patients (p < 0.05 vs lean subjects) but not in obese non-diabetic patients compared to lean control subjects (Table 2) .
Statistical analysis
All data are expressed as mean _+ SEM unless stated otherwise. Data were averaged to a single value for periods -60-0 rain (except for glucose kinetics for which the period -30 0 min was considered) and 120-180 min. Comparisons between healthy volunteers, obese non-diabetic subjects and obese NIDDM patients were performed during each of these two periods with modified analysis of variance and unpaired t-tests. Comparison
Effects of fructose ingestion on glucose metabolism in young healthy lean subjects, middle-aged obese nondiabetic subjects, and middle-aged obese NIDDM patients (protocol 1). The effects of fructose ingestion on plasma glucose, fructose, 13C glucose APE and breath 13CO2 APE are shown in Figure 1 . Fructose ingestion slightly increased plasma glucose and markedly decreased plasma non-esterified fatty acid concentrations in all three groups of subjects ( Fig. 1 ; Table 1 ). Plasma fructose concentrations were slightly higher in obese non-diabetic subjects than in lean subjects (p < 0.05). EGP(F) was slightly lower in obese non-diabetic and in obese NIDDM subjects, but the difference was not significant. EGP was not altered by fructose ingestion although 13C glucose synthesis contributed 73.2 % of EGP in lean subjects, 62.6 % in obese non-diabetic subjects, and 52.8 % in obese NIDDM patients ( Table 2) . The stimulation by fructose of net CHO oxidation and the inhibition of net lipid oxidation were similar in obese and lean subjects. In NIDDM patients, the stimulation of CHO oxidation and of fructose oxidation and the inhibition of net lipid oxidation were blunted, resulting in a marked increase in net non-oxidative CHO disposal and in a slight increase in non-oxidative fructose disposal (Table 3 ). This non-oxidative fructose disposal indicates an increased rate of net glycogen deposition and/or de novo lipogenesis.
Effects of hyperglucagonaemia + fructose on glucose metabolism in healthy lean subjects (protocol 2).
Infusion of glucagon increased plasma glucagon concentrations by 108.0 % (Table 4) . When fructose was ingested during hyperglucagonaemia, EGP increased by 19.8 % (Fig.2) (p < 0.001). However, plasma 13C
glucose enrichment (which is a reflection of the enrichment of the intrahepatic glucose 6-phosphate) was identical with or without glucagon (Fig. 3) , indicating that both glucose synthesized from fructose and glucose originating from other sources (i. e. glycogenolysis and gluconeogenesis from other precursors) contributed equally to this increase in EGE As a consequence of the increase in EGR plasma glucose and insulin were increased by 29.2 (p < 0.01) and 133.3 % (p < 0.001), respectively (Table 4) . 13C fructose oxidation, non-oxidative fructose disposal, and the increment in net CHO ox (Fig. 4) , and net non-oxidative CHO disposal (6.3 + 1.8 vs 7.3 + 2.5 ~tmol 9 kg -1. min -1) were identical without or with hyperglucagonaemia.
Effects of hyperglucagonaemia alone on glucose metabolism in healthy lean subjects (protocol 3).
Infusion of glucagon increased plasma glucagon concentration in the same range as in protocol 2. However, EGP did not increase (Fig. 2) and net CHO oxidation tended to increase (Fig. 4) (p = 0.14) while lipid oxidation decreased slightly (p --0.052). Slight rises in plasma glucose levels (from 4.8 + 0.1 to 5.4 + 0.1 mmol/1, p < 0.01) and insulin levels (from 28.5_+ 5.6 to 35.3_+ 3.6 pmol/1,p < 0.01) were also observed (Table 4) .
Discussion
Obese NIDDM subjects had an increased basal EGP [6, 9] , the mechanisms of which remain unidentified. It has been suggested that an increased hepatic lipid oxidation may promote gluconeogenesis and secondarily enhance hepatic glucose production [25] [26] [27] [28] . In the present study, our obese patients with normal glucose tolerance had increased concentrations of plasma non-esterified fatty acids and increased lipid oxidation rate. They also had higher than normal plasma insulin concentrations, suggesting insulin resistance. Their basal EGP was normal however, indicating that other factors are involved in the increased basal EGP of NIDDM patients. Fructose ingestion failed to increase EGP in lean individuals, obese non-diabetic subjects, and obese patients with NIDDM. Gluconeogenesis was nonetheless a major pathway of 13C fructose disposal, as indicated by a significant increase in plasma 13C glucose APE. This process appeared to be stimulated to the same extent in both groups of subjects. The slight rise in plasma glucose and insulin concentrations induced by fructose may possibly have contributed to inhibit glycogenolysis and hepatic glucose output. However, it has been demonstrated that EGP does not increase in healthy humans infused with fructose even when plasma insulin and glucagon are maintained at constant levels by infusions of somatostatin, insulin and glucagon; since plasma glucose was also constant in these experiments, it indicated autoregulation of hepatic glucose production in healthy humans [5] .
An increased glycogen synthesis has been shown to participate in the autoregulation of hepatic glucose production in healthy lean subjects [5] and is therefore likely to also function in obese NIDDM subjects. Non-oxidative fructose disposal, which corresponds to glycogen accretion from neoformed glucose [5] and de novo lipogenesis [29] were identical in lean subjects, obese non-diabetic subjects and obese patients with NIDDM. This suggests that stimulation of glycogen synthesis contributed to prevent an increase in EGP after fructose ingestion in all three groups. The failure of an increased glucose synthesis from fructose to enhance overall EGP in NIDDM mirrors the observation by other investigators that inhibition of gluconeogenesis in NIDDM patients did not decrease EGP and plasma glucose concentrations [30] . Together, these observations indicate that EGP also remains constant in obese non-diabetic subjects and in obese patients with NIDDM when gluconeogenesis is stimulated at the substrate level.
Incidentally, fructose concentrations were somewhat higher in obese compared to lean subjects. We have no obvious explanation for this difference. Although the fructose dose was normalized for FFM, differences in blood volume may possibly account for this variation. Alternatively, first pass hepatic extraction of fructose may be decreased in obese patients; however, their EGP was normal both in the basal state and during fructose administration. In all three groups of subjects, fructose concentration did not significantly change during the 3rd hour of administration, suggesting that hourly fructose absorption was roughly equal to hourly fructose ingestion by this time.
Glucagon plays a central role in the regulation of EGE However, the autoregulation of EGP does not involve suppression of glucagon secretion because it is also present when glucagon concentrations are maintained constant by means of infusions of somatostatin and exogenous glucagon [2, 5] . Hyperglucagonaemia is nonetheless, frequently found in NIDDM patients, and many stimulate gluconeogenesis and EGP from an increased supply of endogenous gluconeogenic precursors. In order to further delineate the effects of hyperglucagonaemia on substrateinduced EGR healthy subjects were further studied during ingestion of fructose with hyperglucagonaemia or during hyperglucagonaemia alone. In lean subjects, ingestion of 13C fructose during moderate hyperglucagonaemia led to a 20 % increase in EGR The subsequent rise in blood glucose level was, however, modest, most likely due to a simultaneous increase in insulin secretion which stimulated peripheral glucose uptake, but may also have limited EGR Glucagon alone failed to increase EGR but induced a slight rise in plasma glucose and insulin. This stimulation of insulin secretion has been shown to be responsible for the inhibition of a glucagon-induced rise in hepatic glucose output [31] . It appears unlikely that glucagon increased EGP merely by increasing fructose conversion into glucose because fructose enters the gluconeogenic pathway at the level of the triose-phosphates, thus by-passing the major gluconeogenic steps controlled by glucagon. Non-oxidative fructose disposal, which corresponds to gluconeogenesis and de novo lipogenesis was not affected by glucagon. Glucagon may have increased the former while decreasing the latter, but such an effect is also unlikely because de novo lipogenesis is an energy-requiring process [32] and energy expenditure was not reduced by glucagon. EGP is the result of several processes including a) the glycogenolytic and gluconeogenic pathways which both contribute to the intrahepatic glucose-6-phosphate pool, b) glycogen synthesis and hydrolysis of glucose-6-phosphate, which together account for glucose-6-phosphate disposal. The absence of alterations in plasma 13C glucose enrichment (which reflects the enrichment of intrahepatic glucose-6-phosphate) indicates that the relative rates of: a) 13C glucose synthesis from fructose and b) production of unlabelled glucose from glycogen and other gluconeogenic precursors did not change during hyperglucagonaemia. This points to an activation of net glucose-6-phosphate hydrolysis during hyperglucagonaemia which may be due to a stimulation of glucose-6-phosphatase or an inhibition of hepatic glucokinase activities. Alternatively, the inhibition by glucagon of glycogen synthase may have led to an increase in glucose-6-phosphate concentration, which may have increased the flux through glucose-6-phosphatase. The hypothesis that glucagon may play a key role in channelling glucose-6-phosphate towards its systemic release at the expense of glycogen synthesis finds support in the literature. In fasted dogs, acute suppression of glucagon secretion by an infusion of somatostatin and insulin to maintain basal insulin concentrations decreased EGP and the conversion of gluconeogenic precursors to plasma glucose, while simultaneously increasing hepatic glycogen content [33] . A similar observation was made in dogs infused for 3 days with stress hormones when glucagon infusion was abruptly stopped and the infusions of cortisol, epinephrine and growth hormone were continued [34] . Interestingly, neither fructose nor hyperglucagonaemia alone produced such effects. This indicates that fructose and glucagon produce two distinct alterations that act together to increase EGR Fructose may have altered the intra-hepatic concentrations of one or several regulatory metabolites, while glucagon may have affected the activity of key enzymes on the pathways of glycogen synthesis and/or glucose-6-phosphate hydrolysis. It is furthermore tempting to speculate that these metabolic alterations were already present in obese NIDDM patients in the basal state, and were responsible for part or all of the enhanced EGE We conclude that during fructose administration: 1) gluconeogenesis is increased, but EGP remains constant in NIDDM, obese non-diabetic, and lean subjects; 2) in lean subjects, both an increased glucagonaemia and an enhanced supply of gluconeogenic precursors are required to increase EGP; this increase in EGP occurs without changes in the relative proportion of glucose 6-phosphate production from fructose and from other sources (i.e. glycogenolysis + gluconeogenesis from non-fructose precursors).
